 |
Hectorol News
Healthcare Professionals: Hectorol co-pay coupons are now available!
Genzyme Reports New Study Showing Lower Mortality Risk with Vitamin D2 Therapy
Genzyme has been named Associate Sponsor of the National Kidney Fund’s Kidney Early Evaluation Program (KEEP)
Hectorol is indicated for the treatment of secondary hyperparathyroidism in patients with stage 3 or stage 4 chronic kidney disease (capsules) and in patients with chronic kidney disease on dialysis (capsules and injection). Hectorol effectively reduces PTH across CKD stage 3, stage 4, and stage 5 on dialysis. Hectorol maintains 1,25D levels within the normal physiologic range[1] for up to 48 hours.[2] This website provides information regarding secondary hyperparathyroidism and treatment with Hectorol. |
|
 |
|
|
|
|
|
|
|
|
|
 |
|
|
 |
|
|
|
|
|
|
References
1. Bailie GR, Johnson CA. Comparative review of the pharmacokinetics of vitamin D analogs. Seminars in Dialysis. 2002;15:352-357
2. Upton RA, Knutson JC, Bishop CW, et al. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. Nephrol Dial Transplant. 2003;18:750-758
|
|
|
hec_m_safety_info
Hectorol is indicated for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease (capsules) and in patients with chronic kidney disease on dialysis (capsules and injection)∙ Hectorol is contraindicated in patients with a tendency towards hypercalcemia or evidence of vitamin D toxicity ∙ Overdosage of any form of vitamin D is dangerous∙ Acute hypercalcemia may exacerbate tendencies for cardiac arrhythmias and seizures and may potentiate the action of digitalis drugs∙ Chronic hypercalcemia can lead to generalized vascular and soft tissue calcification∙ Pharmacologic doses of vitamin D and its derivatives should be withheld during Hectorol treatment to avoid possible additive effects and hypercalcemia∙ Magnesium-containing antacids and Hectorol should not be administered concomitantly∙ Adverse effects of Hectorol treatment are: hypercalcemia, hyperphosphatemia, hypercalciuria, and oversuppression of iPTH∙ Adverse events reported by ³ 5% of the Hectorol-treated predialysis patients included: infection, chest pain, constipation, dyspepsia, anemia, dehydration, depression, hypertonia, insomnia, paresthesia, increased cough, dyspnea and rhinitis ∙ Adverse events reported by ³ 5% of the Hectorol-treated dialysis patients included: headache, malaise, bradycardia, nausea/vomiting, edema, dizziness, dyspnea, and pruritus. See Hectorol Capsules Full Prescribing Information or Hectorol Injection Full Prescribing Information.
|
|
|
|
|
|
|
|
|
|
 |
| Contact |
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
T: 800 847 0069
F: 617 252 7600
Email
|
 |
|
|
|
|
|
Home
Genzyme Corporate
